Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) Cash from Operations (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Cash from Operations for 5 consecutive years, with 3803000.0 as the latest value for Q4 2020.

  • On a quarterly basis, Cash from Operations fell 482.39% to 3803000.0 in Q4 2020 year-over-year; TTM through Dec 2020 was 18423000.0, a 564.85% decrease, with the full-year FY2024 number at 30700000.0, down 6.95% from a year prior.
  • Cash from Operations was 3803000.0 for Q4 2020 at Forte Biosciences, up from 7739000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 16117000.0 in Q2 2019 to a low of 17682000.0 in Q1 2019.
  • A 5-year average of 5816750.0 and a median of 7460000.0 in 2017 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: soared 249.74% in 2019, then tumbled 1299.46% in 2020.
  • Forte Biosciences' Cash from Operations stood at 7748000.0 in 2016, then dropped by 18.38% to 9172000.0 in 2017, then plummeted by 30.21% to 11943000.0 in 2018, then skyrocketed by 94.53% to 653000.0 in 2019, then crashed by 482.39% to 3803000.0 in 2020.
  • Per Business Quant, the three most recent readings for FBRX's Cash from Operations are 3803000.0 (Q4 2020), 7739000.0 (Q3 2020), and 4016000.0 (Q2 2020).